



Published in final edited form as:

*Nat Genet.* 2009 February ; 41(2): 168–177. doi:10.1038/ng.302.

## Increased LIS1 expression affects human and mouse brain development

Weimin Bi<sup>1,2,15</sup>, Tamar Sapir<sup>3,15</sup>, Oleg A Shchelochkov<sup>1,4,15</sup>, Feng Zhang<sup>1</sup>, Marjorie A Withers<sup>1</sup>, Jill V Hunter<sup>4</sup>, Talia Levy<sup>3</sup>, Vera Shinder<sup>5</sup>, Daniel A Peiffer<sup>6</sup>, Kevin L Gunderson<sup>6</sup>, Marjan M Nezarati<sup>7</sup>, Vern Ann Shotts<sup>8</sup>, Stephen S Amato<sup>9</sup>, Sarah K Savage<sup>9</sup>, David J Harris<sup>10</sup>, Debra-Lynn Day-Salvatore<sup>11</sup>, Michele Horner<sup>11</sup>, Xin-Yan Lu<sup>1,2</sup>, Trilochan Sahoo<sup>1,2</sup>, Yuchio Yanagawa<sup>12</sup>, Arthur L Beaudet<sup>1,4,13</sup>, Sau Wai Cheung<sup>1,2</sup>, Salvador Martinez<sup>14</sup>, James R Lupski<sup>1,2,4,13</sup>, and Orly Reiner<sup>3</sup>

James R Lupski: jlupski@bcm.tmc.edu; Orly Reiner: orly.reiner@weizmann.ac.il

<sup>1</sup>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA

<sup>2</sup>Medical Genetics Laboratories, Baylor College of Medicine, Houston, Texas 77030, USA

<sup>3</sup>Department of Molecular Genetics, The Weizmann Institute of Science, 76100 Rehovot, Israel

<sup>4</sup>Texas Children's Hospital, Houston, Texas 77030, USA

<sup>5</sup>Department of Chemical Research Support, The Weizmann Institute of Science, 76100 Rehovot, Israel

<sup>6</sup>Illumina, Inc., San Diego, California 92024, USA

<sup>7</sup>North York General Hospital, Toronto, Ontario M2K1E1, Canada

<sup>8</sup>Arkansas Children's Hospital, Little Rock, Arkansas 72202, USA

<sup>9</sup>Eastern Maine Medical Center, Bangor, Maine 04401, USA

<sup>10</sup>Children's Hospital, Boston, Massachusetts 02115, USA

<sup>11</sup>Institute for Genetic Medicine, Saint Peters University Hospital, New Brunswick, New Jersey 08901, USA

<sup>12</sup>Department of Genetic and Behavioral Neuroscience, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan

© 2009 Nature America, Inc. All rights reserved.

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions/>

Correspondence to: James R Lupski, [jlupski@bcm.tmc.edu](mailto:jlupski@bcm.tmc.edu); Orly Reiner, [orly.reiner@weizmann.ac.il](mailto:orly.reiner@weizmann.ac.il).

<sup>15</sup>These authors contributed equally to this work.

Note: Supplementary information is available on the Nature Genetics website.

**Author Contributions:** W.B. coordinated human studies and conducted real time RT-PCR assays. T.S. produced transgenic mice and conducted mouse studies. O.A.S. recruited patients and reviewed clinical data. F.Z. conducted high-density array CGH and breakpoint analyses. M.A.W. carried out cell culture. J.V.H. reviewed the MRI data. T.L., V.S. and S.M. assisted in mouse analyses. Y.Y. provided GAD67-GFP mice. D.A.P. and K.L.G. conducted SNP genotyping. M.M.N., V.A.S., S.S.A., S.K.S., D.J.H., D.-L.D.-S., M.H. and A.L.B. recruited and clinically characterized patients. S.W.C., X.-Y.L. and T.S. were involved in cytogenetic and clinical array CGH studies. J.R.L. and O.R. were involved in research design and data analyses. W.B., T.S., O.A.S., O.R. and J.R.L. prepared the manuscript.

<sup>13</sup>Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA

<sup>14</sup>Instituto de Neurociencias, UMH-CSIC, San Juan de Alicante, Alicante 03550, Spain

## Abstract

Deletions of the *PAFAH1B1* gene (encoding LIS1) in 17p13.3 result in isolated lissencephaly sequence, and extended deletions including the *YWHAE* gene (encoding 14-3-3ε) cause Miller-Dieker syndrome. We identified seven unrelated individuals with submicroscopic duplication in 17p13.3 involving the *PAFAH1B1* and/or *YWHAE* genes, and using a ‘reverse genomics’ approach, characterized the clinical consequences of these duplications. Increased *PAFAH1B1* dosage causes mild brain structural abnormalities, moderate to severe developmental delay and failure to thrive. Duplication of *YWHAE* and surrounding genes increases the risk for macrosomia, mild developmental delay and pervasive developmental disorder, and results in shared facial dysmorphologies. Transgenic mice conditionally overexpressing LIS1 in the developing brain showed a decrease in brain size, an increase in apoptotic cells and a distorted cellular organization in the ventricular zone, including reduced cellular polarity but preserved cortical cell layer identity. Collectively, our results show that an increase in LIS1 expression in the developing brain results in brain abnormalities in mice and humans.

---

The extent to which copy-number variation (CNV) has a role in human genetic variation has emerged only recently after the development of genome-wide tools. Genomic rearrangement mutations are rather common, and one of the premises underlying our research is that the likelihood for dosage-sensitive loci to show both deletion and duplication phenotypes is high<sup>1</sup>. Furthermore, existing knowledge supports the notion that the deletion phenotype is anticipated to be more severe than the duplication phenotype. One such locus, in which deletions are manifested as a severe brain malformation, is the *PAFAH1B1* gene, encoding LIS1 (ref. 2). Deletions or point mutations in this gene result in a spectrum of abnormal neuronal migration phenotypes ranging from classic lissencephaly to subcortical band heterotopia<sup>3</sup>. Aberrant neuronal migration may be responsible for a substantial proportion of cases of mental retardation and epilepsy in children<sup>4</sup>. Furthermore, diseases such as schizophrenia, autism and dyslexia are associated with deviant migration of neurons<sup>5,6</sup> and *de novo* CNVs involving multiple different genomic regions<sup>7–13</sup>. To date, the issue of whether *PAFAH1B1* duplication results in a disease phenotype has not been systematically investigated.

A contiguous gene deletion including *PAFAH1B1*, mapping within the subtelomeric region of chromosome 17p, is associated with Miller-Dieker syndrome (MDS; OMIM 247200)<sup>14</sup>. Individuals with MDS show a more severe brain phenotype accompanied by marked dysmorphic facial appearances; other congenital anomalies depend on the extent of the deletion. The candidate gene for the more severe brain phenotype is *YWHAE*, encoding 14-3-3ε, located within the MDS critical region<sup>15</sup>. Given the above, we hypothesized that increased copy number within the MDS locus is involved in human disease. In support of this hypothesis, complete trisomy of the short arm of chromosome 17 was suggested to comprise a new syndrome owing to the similar phenotypic appearance<sup>16,17</sup>. Until now, there were no reported submicroscopic tandem duplications in 17p13.3 in the MDS region.

*PAFAH1B1* is an important gene in this region; sensitivity to its reduced expression has been shown in mouse models<sup>18,19</sup>. Furthermore, cell-autonomous reduction of *LIS1* levels results in significant inhibition of neuronal migration and proliferation<sup>20–22</sup>.

Here we used biological data derived from the developing mouse brain combined with careful screening by genome-wide array comparative genomic hybridization (array CGH) for CNVs involving specific genes in humans. We assessed seven individuals with relatively small submicroscopic duplications in 17p13.3, including *PAFAH1B1* and/or the *YWHAE*, *CRK* and *MYO1C* genes in the MDS critical region, identified by array CGH. Using reverse genomics approaches, ‘genomotype’-phenotype association suggested that the duplications of *PAFAH1B1* or *YWHAE* cause two different disorders. Common features observed in individuals with *PAFAH1B1* duplications include neurobehavioral deficits and subtle brain abnormalities. We also generated transgenic mice that conditionally overexpressed *LIS1* in the developing brain. Our results show that an increase in *LIS1* expression in the developing brain may result in smaller brains and neuronal migration abnormalities in mice and that more than one gene mapping within a duplication may interact to bring about a phenotype. The abundance of CNVs has emphasized the complexity of defining normal and abnormal variability. These results enhance our understanding of the biological processes underlying human disease, document that subtle overexpression of a normal gene can have profound phenotypic consequences, and indicate optimal diagnostic and possible future therapeutic approaches.

## Results

### Duplications in 17p13.3, including the MDS critical region

Using array CGH, we detected a gain of copy number in the MDS critical region in seven unrelated individuals (Fig. 1; representative photographs and brain MRI are shown in Fig. 2). We did not identify copy number changes in other interrogated loci. A duplication in 17p13.3 was confirmed by FISH analyses in four individuals (Fig. 1g–i,k), whereas subject 6 had a complex rearrangement consisting of a triplication of *PAFAH1B1* (Fig. 1j) embedded within a duplicated region. The duplicated segment in subject 2 was inserted on the long arm of one chromosome 13 (Fig. 1h). Parental analysis showed that the duplications in subjects 1, 3, 4, 6 and 7 were *de novo*; in subject 5, it was maternally inherited, and for subject 2, only one normal parent was available.

### Inferring mechanisms from junction sequences

By conducting array CGH analysis using a high-density oligonucleotide-based custom array for the short arm of chromosome 17 in these seven subjects, we precisely mapped the duplications in the MDS region and showed that the proximal and distal breakpoints were unique to each individual (Fig. 1a). Subjects 1, 2, 3 and 4 showed duplications in the distal MDS region containing *YWHAE* but not *PAFAH1B1*. Subject 1 had the smallest duplication (Figs. 1a and 3a), which comprised 240 kb and contained only four genes (*TUSC5*, *YWHAE*, *CRK* and *MYO1C*); exon 1 of several *MYO1C* transcripts were excluded from the duplicated region. Subjects 5 and 6 showed a gain in copy number in the proximal MDS region including *PAFAH1B1*. Subject 7 had a large duplication including both *PAFAH1B1* and

*YWHAE*. Genome-wide SNP genotyping<sup>23</sup> on subjects 2 and 7 (Supplementary Fig. 1 online) revealed no additional potential pathological copy number changes.

High-density array CGH showed that the duplicated region in subject 5 was separated by an ~50-kb region with a normal copy number (Figs. 1a and 3b). The proximal duplication was ~151 kb and included the complete *PAFAH1B1* gene. The distal duplication was ~580 kb. The same complex rearrangement was also present in the mother, as determined by array CGH and PCR analysis of the breakpoints. Subject 6 had a complex rearrangement with a 160-kb triplication flanked by a distal 266-kb duplication and a proximal 205-kb duplication (Figs. 1a and 3c). The triplication included the complete *PAFAH1B1* gene. In addition, we identified an 82-kb deletion distal to the MDS region that was inherited from the father (Fig. 3c). We identified a maternally inherited ~4-kb deletion within the large duplication in subject 7 (Figs. 1a and 3d). Thus, the *de novo* duplication in subject 7 was a simple rearrangement.

Three of the described duplications were complex (subjects 2, 5 and 6) and may have arisen by the recently described mechanism of replication fork stalling and template switching (FoSTeS)<sup>24</sup>. DNA sequencing of the junction points suggested that the complex rearrangement in subject 5 was caused by two FoSTeS events; further studies are necessary to explain the complex rearrangement in subject 6 (Supplementary Fig. 2 online). We obtained junction sequences for the three subjects with apparent simple tandem duplications (Fig. 3e). For subjects 1 and 4, the breakpoints were located within unique sequences with no repetitive elements. Microhomology between the distal and proximal breakpoints was present, with 6 bp (CTGGCT) of perfect identity for subject 1 and 2 bp (GC) for subject 4. The breakpoints in subject 3 were within two *AluSg* elements, and the crossover was mapped to a 27-bp interval. Thus, the duplications in subjects 1 and 4 probably occurred through either nonhomologous end-joining or by a single FoSTeS event, whereas the duplication in subject 3 apparently occurred by nonallelic homologous recombination between two repetitive elements.

### Overexpression of genes within the duplicated region

We conducted gene expression analysis on lymphoblasts by real-time RT-PCR (Supplementary Table 1 online). In subject 4, who had a duplication including *YWHAE* and *CRK*, expression of *YWHAE* and *CRK* was higher, whereas expression of *PAFAH1B1* was consistent with that of normal controls. *PAFAH1B1* expression was also higher in subject 5, who had a duplication including *PAFAH1B1*, whereas expression of *YWHAE* and *CRK* was similar to that of normal controls. Thus, expression of the genes in the MDS region was consistent with their genomic copy number.

### Genomotype-phenotype association studies on dup17p13.3

The key physical, cognitive and laboratory findings for the seven affected individuals are summarized in Table 1; detailed clinical descriptions are provided in Supplementary Note online. Although only a small cohort ( $n = 7$ ) of individuals with duplications was available in this study, and further studies will be needed to better delineate the clinical consequences of 17p13.3 duplications, we drew some conclusions about potential genomotype-phenotype

associations. The individuals with duplications including *YWHAE* were characterized by a milder neurocognitive and pervasive developmental disorder phenotype, as well as sharing some minor craniofacial abnormalities, whereas the duplication of *PAFAH1B1* predisposed to severe total body growth restriction and moderate to severe developmental delay.

Some craniofacial features were shared among individuals with *YWHAE* duplication, including mild synophrys, overhanging columella, thin upper lip and pointed chin (Fig. 2a–g). However, there was no apparent pathognomonic clinical facial dysmorphism or facial gestalt apparent from this limited case series. Individuals with *PAFAH1B1* duplication were not particularly dysmorphic (Fig. 2h–j). A macrosomia tendency was noted in individuals with the *YWHAE* duplication, with the exception of subject 3, who showed normal morphometric parameters. This was contrasted by microcephaly and severe growth restriction in individuals with *PAFAH1B1* duplication. Major internal organ abnormalities were more characteristic for the individuals with duplication of *PAFAH1B1*. Other abnormalities include craniosynostosis, intestinal malrotation, scoliosis, cardiovascular anomaly and varus leg deformity.

Developmental delay, features of pervasive developmental disorder and cognitive difficulties and/or speech abnormalities were observed in all affected individuals and were the primary reason for referral to genetics or neurology departments. Subject 4 showed only mild fine-motor delays by age 15 years. Common neurobehavioral problems included pervasive developmental disorder and attention deficit–hyper-activity disorder observed in individuals with *YWHAE* duplication. The duplication in subject 5 was inherited from his mother, who also had attention deficit–hyperactivity disorder and suffered from seizures.

*PAFAH1B1* haploinsufficiency causes lissencephaly, with severity ranging from complete agyria to variable degrees of agyria and pachygyria and, rarely, subcortical band heterotopia<sup>25,26</sup>. In contrast, overexpression of *LIS1* resulting from *PAFAH1B1* duplication seems to cause different and subtle brain structural phenotypes. Subject 6, who had a triplication of *PAFAH1B1*, showed mild cerebral volume loss and gross dysgenesis of the corpus callosum with marked cerebellar atrophy (Fig. 2k). In addition, the brain appeared smaller, mainly in the occipital cortex. Subject 7, who had a duplication of *PAFAH1B1*, showed thinning of the splenium of the corpus callosum, mild cerebellar volume loss (Fig. 2l) and a smaller brain, mainly in the occipital cortex. In general, magnetic resonance imaging (MRI) abnormalities were more pronounced both qualitatively and quantitatively in the individual with *PAFAH1B1* triplication compared to duplication, an observation consistent with a gene dosage effect.

### **LIS1-overexpressing mice have smaller brains**

Given the limited resolution of brain MRI, and to understand the molecular mechanisms underlying the mild brain structural abnormalities in individuals with *PAFAH1B1* duplication, we analyzed trans-genic mice with increased *LIS1* expression in the developing brain. Expression of the *Tg(CAGG-loxP-LacZ-neo-loxP-PAFAH1B1-DsRed)* transgene (abbreviated as *LIS1-DsRed*) was clearly noticeable at embryonic day 12.5 (E12.5; Fig. 4a) and was estimated to be a 20% increase over endogenous protein levels (Fig. 4b). Overall, the brains of *LIS1::Foxg1(Cre)* mice (*Foxg1<sup>tm1(Cre)Skw</sup>* transgenic mice, referred to here as

*Foxg1(Cre)*, crossed with *LIS1-DsRed* transgenic mice) were smaller than those of control mice (Fig. 4c–f). Measurements of brain width at ventral positions at E14.5 were significantly smaller for *LIS1::Foxg1(Cre)* mice (mean  $\pm$  s.e.m.,  $295.9 \pm 7.213 \mu\text{m}$ ) than for control mice ( $322.9 \pm 8.004 \mu\text{m}$ ;  $P < 0.0001$  by paired Student *t* test). Postnatal brains of *LIS1::Foxg1(Cre)* mice showed a reduction mainly in layer 4 (the somatosensory cortex), which appeared reduced to a vestigial layer with few granular cells and half of its normal thickness and showed an evident reduction of barrel field extension (Supplementary Fig. 3 online). Brain sections showed disorganization in the ventricular zone, as assessed by Hoechst staining of live sections (Fig. 4g,h). Immunostaining for Tbr2 combined with short bromo-deoxyuridine (BrdU) labeling also revealed a reduction mainly in the ventricular zone width, but not the subventricular zone width (where Tbr2-positive cells are concentrated; Fig. 4i,j).

Within the ventricular zone, progenitors divide at apical positions close to the ventricle. In *LIS1::Foxg1(Cre)* brains, we detected a wider distribution of mitotic cells by immunostaining of phosphorylated histone H3 present in late G2/M phase (Fig. 4k,l). In addition, the number of cells with phosphorylated histone H3 was significantly higher in the LIS1-overexpressing brain sections than in control sections ( $P < 0.0001$  by paired *t* test;  $12.83 \pm 0.542$  for *LIS1::Foxg1(Cre)* versus  $10 \pm 0.447$  for control). No differences were noted when we compared different control brain sections, including Cre-control (*Foxg1(Cre)*) mice, mice carrying the transgene but no Cre, and wild-type control mice. Nestin expression was also higher in *LIS1::Foxg1(Cre)* mice than in control mice (Fig. 4m,n). The aberrant position of mitotic cells and greater nestin immunoreactivity were accompanied by an increase in apoptotic cells, as determined by TUNEL (Fig. 4o,p). The number of TUNEL-positive cells in LIS1-overexpressing hemicortex in coronal brain sections was  $14.26 \pm 1.128$ ; in Cre-expressing control mice, the number was significantly lower ( $9.5 \pm 1.288$ ,  $P < 0.05$ ) and similar to that in wild-type brain sections ( $7.00 \pm 0.663$ ,  $P < 0.001$  by Dunn multiple-comparison test; Fig. 4q). There was no significant difference between Cre-control and wild-type brain sections. Despite the disorganization of the ventricular zone, cortical layer identity was preserved (Supplementary Fig. 3g–p), and radial glia scaffold was aligned in a normal pattern (Supplementary Fig. 3c).

### LIS1 overexpression affects cell polarity in the ventricular zone

Polarity is one of the main features of neuroepithelial cells in the ventricular zone. To further investigate the disorganized ventricular zone in *LIS1::Foxg1(Cre)* mice, we analyzed cell polarity in this area. The ventricular zone has apical-basal polarity, with proliferating progenitors on the ventricular-apical surface decorated with adherens junctions<sup>27</sup>. Staining with several markers of cell polarity and adhesion revealed disruptions in apical junctions and a reduction in cell polarity (Fig. 5a–l). We also observed an apparent mislocalization of  $\beta$ -catenin immunostaining (Fig. 5a,b). In control brain sections,  $\beta$ -catenin was prominently located in punctate structures near the ventricle; in LIS1-overexpressing mice,  $\beta$ -catenin-positive punctate dots were distributed throughout the cell with no polar staining pattern. In addition, the pattern of actin localization close to the ventricle was wider, and the dense patches detected by phalloidin staining were not observed (Fig. 5c,d). Centrosomes, which are usually tethered to the apical surface, were scattered (Fig. 5e,f). Numb, which usually

localizes only to the apical side, was widely distributed in the cytoplasm (Fig. 5g,h). The observed changes were accompanied by a marked reduction in cadherin immunostaining (Fig. 5i,j).

Additional polarity markers such as atypical protein kinase C (aPKC) and PAR6 (Fig. 5k–n) are usually highly concentrated in the ventricular surface. In LIS1-overexpressing brains, we observed a noncontinuous band of aPKC expression (Fig. 5k,l, arrowheads) with reduced PAR6 expression (Fig. 5m,n). Electron microscopy studies (Fig. 5o–t) revealed progenitors at the ventricular zone that were only partially polarized in LIS1-overexpressing brain sections, in comparison to the organized cells of control (Fig. 5o,r) or Cre-control (Fig. 5p,s) brains. The abundance of adherens junctions was reduced in LIS1-overexpressing brain sections, and in many cells with adherens junctions, the junctions were not organized perpendicular to the ventricular surface as in control cells (Fig. 5o–t). The micrographs also revealed an increase in the number of apoptotic cells compared to controls (data not shown).

Time-lapse microscopy of embryonic brain sections detected a marked effect on nuclear motility in the ventricular zone (Supplementary Movies 1 and 2 online). In control brain sections, we observed prototypical interkinetic nuclear movement, whereas in sections from LIS1-overexpressing littermates, cells moved significantly faster than control cells ( $P = 0.0004$  by Mann-Whitney test; average velocity  $86.96 \pm 5.447 \mu\text{m/h}$  for LIS1-overexpressing nuclei ( $n = 81$ ) versus  $54.35 \pm 3.917 \mu\text{m/h}$  for controls ( $n = 58$ )) and in random orientations. Velocity frequency distribution revealed that most control nuclei showed similar velocities, whereas nuclei of LIS1-overexpressing cells were distributed among multiple velocity bins (Supplementary Fig. 4 online). Furthermore, the activity of a key regulator of neuronal polarity, Cdc42, was lower in brain lysates from LIS1-overexpressing mice (Fig. 5u). Collectively, these results show that increased LIS1 expression reduced cellular polarity in the ventricular zone.

### LIS1 overexpression affects radial and tangential migration

We tested whether LIS1 overexpression affects neuronal migration. We evaluated two routes of migration: radial and tangential. Neurons born in the ventricular zone migrate radially to their appropriate position in the cerebral cortex. Early-born neurons form the preplate, which is split after radial migration of later-born neurons. In control mice at E14.5, the cortical plate is already visible in the lateral and dorsal regions of the pallium. In LIS1-overexpressing E14.5 littermates, we noted a delay in preplate splitting (Fig. 6a,b). A delay in radial migration was identified by cell counts in BrdU experiments at E13.5 and examined at E15.5 (Fig. 6c) or postnatal day 0 (P0; Fig. 6d–e). We observed a delay in tangential migration at E12.5 and E14.5 by genetic labeling of the interneuron population (glutamic acid decarboxylase-green fluorescence protein knock-in mice ( $\text{GAD67-GFP}(\text{neo})$ )<sup>28</sup> crossed with  $\text{LIS1}::\text{Foxg1}(\text{Cre})$  mice; Fig. 6f–k). These results were corroborated by an observable reduction in the number of migrating calbindin-positive interneurons found in the P0 cerebral cortex (Fig. 6l,m). In summary, LIS1 overexpression affected both radial and tangential migration.

## Discussion

Diseases resulting from structural changes of the genome have been referred to as genomic disorders<sup>1,29</sup>. Our findings increase the repertoire of known genomic disorders within the MDS locus, and combined data derived from a mouse model enabled us to further delineate clinical phenotypes and attribute them to CNVs of crucial genes. The seven duplications described here are nonrecurrent, with all of the breakpoints distinct from each other. The three complex rearrangements and two of the three simple duplications we analyzed probably occurred by the DNA-replication FoSTeS mechanism<sup>24</sup>.

Our conclusion that the observed phenotypes may be associated with increased expression of specific genes is based on several observations, including real-time RT-PCR results. The seven individuals described here all share developmental delays and some cognitive difficulties and/or speech abnormalities, but they vary in other clinical manifestations (Fig. 7). Individuals with duplications including *YWHAE* showed distinct facial features that were not observed in subjects with *PAFAH1B1* duplication. Likewise, individuals with extended deletions in the MDS locus show facial dysmorphologies<sup>14</sup>. An overgrowth phenotype or relatively higher body weight and/or length were observed in individuals with a duplication including *YWHAE* ( $n = 4$ ), except for the individual with a normal copy number of *CRK* and *MYOIC*. Overgrowth (within the normal growth curve) is relatively rare in the large category of individuals carrying genomic rearrangements. The tendency of macrosomia may be attributed to *CRK* being involved in growth regulation and cell differentiation<sup>30</sup>.

Subject 7, with a large duplication including both *PAFAH1B1* and *YWHAE*, showed no apparent facial dysmorphologies and a relatively higher body weight. These findings may underscore possible genetic interactions among genes located in the MDS locus. A genetic interaction has been noted between *LIS1* and 14-3-3 $\epsilon$ , both of which participate in regulation of neuronal migration<sup>15</sup>. Nevertheless, an additional genetic interaction between *LIS1* and *CRK* may be important in regulating neuronal migration. Both *LIS1* and *CRK* bind to phosphorylated *DAB1* downstream of the reelin pathway, which is essential to cortical development<sup>31-33</sup>.

Individuals with *PAFAH1B1* duplication showed cognitive, neuro-behavioral and subtle brain abnormalities; the dosage effect was exacerbated in the individual with triplication of *PAFAH1B1*. Notably, the brains of those individuals were smaller mainly in the occipital cortex, which is also more affected in individuals with *PAFAH1B1* deletions<sup>26</sup> and in mutant mice, consistent with the developmental expression gradient<sup>18</sup>. In addition to *PAFAH1B1*, there are six more known genes (*SMG6*, *SRR*, *SGSM2*, *MNT*, *METT10D* and *KIAA0664*) within the ~400-kb overlapping region among the three individuals with *PAFAH1B1* duplications. However, the established role of *PAFAH1B1* in individuals with deletions or point mutations and the phenotypes observed in *LIS1*-overexpressing mice support the notion that *LIS1* is a major factor for the brain phenotypes in individuals with *PAFAH1B1* duplications.

One consideration to be addressed is the tendency of isolated DsRed protein to form tetramers<sup>34</sup>. However, the elution profile of brain lysate containing *LIS1*-DsRed from a gel



filtration column was consistent with a predominant dimeric form and did not support the existence of abundant tetrameric forms (Supplementary Fig. 5 online). Previous studies indicated that most LIS1 protein interactions require the dimeric form, thus fully supporting the notion that LIS1-DsRed is functional and in these respects similar to the endogenous protein. The most parsimonious explanation from the aggregate data suggests that phenotypes observed in LIS1-overexpressing mice are caused by increased LIS1 dosage.

Smaller brains and potential migration deficits are recapitulated in conditional trans-genic mice overexpressing LIS1 in the developing brain. We observed an evident reduction of radial and tangential migration in LIS1-overexpressing brains compared to control brains. Furthermore, the brains of LIS1-overexpressing mice were smaller and showed increased apoptosis and partial loss of cell polarity. Our study indicates a role for LIS1 in determining cellular polarity. Among neuronal progenitors within the ventricular zone, it is likely that subgroups differed in their sensitivity to LIS1 dosage, as we observed normal alignment of the radial glia. The neuroepithelium of LIS1-overexpressing mice showed several abnormal features, such as thinning of the ventricular zone, less compact cellular organization, faster motility in unexpected orientations and ectopic positioning of mitotic cells. In the ventricular zone, neural precursors are joined by apical junctional complexes, and intracellular bands of actin stabilize them into a neuroepithelial sheet. The apical junctional complex that links neighboring precursor cells consists of cadherin at the cell surface and  $\alpha$ - and  $\beta$ -catenin in the cytoplasm<sup>7</sup>. Our results indicated a reduction and disorganization of the adherens junctions in brain sections overexpressing LIS1. This was accompanied by a wide distribution of the intracellular protein  $\beta$ -catenin, which was supposed to be linked to the apical junctional complexes. The effect of LIS1 overexpression on the intracellular localization of  $\beta$ -catenin may occur through the known interaction between dynein and  $\beta$ -catenin<sup>35</sup>. In addition, Numb and other polarity markers showed expression differences in LIS1-overexpressing brains. Collectively, LIS1-overexpressing brains showed abnormalities in the neuroepithelium, which may be attributed in part to a partial loss of neuroepithelial polarity.

Our findings are complementary to recent findings, using a conditional knockout model, that LIS1 is essential for neuroepithelial expansion<sup>36</sup>. The polarity-associated activity of LIS1 is most likely to be mediated through regulation of the microtubule-associated molecular motor protein cytoplasmic dynein (reviewed in refs. 37 and 38). Furthermore, a possible genetic interaction between the dynein pathway and the polarity pathway is suggested by the fact that orthologs of LIS1, cytoplasmic dynein and the lissencephaly-associated protein DCX have been shown to affect the first asymmetric cell division in *C. elegans*<sup>14</sup>.

The results of reduced cellular polarity in the ventricular zone are highly variable, even with the same gene involved. For example, conditional knockout of *Cdc42* using various Cre drivers resulted in changes in cell fate<sup>39</sup> or holoprosencephaly<sup>40</sup>, with reduced ventricular cell polarity occurring in both cases. Notably, we observed here a reduction in activated Cdc42, as has been previously observed in *Pafah1b1*<sup>+/-</sup> mice<sup>41,42</sup>. LIS1 may regulate actin polymerization through its interaction with an IQGAP-containing complex<sup>41,42</sup>, thereby activating Cdc42, or through the recently reported interaction of Ndel1 with Cdc42GAP<sup>43</sup>.

Activation of Cdc42 is a key event in cellular polarization, particularly in the nervous system.

Reduced cellular polarity elsewhere in the body may explain the major internal organ abnormalities that were characteristic for individuals with duplication of *PAFAH1B1*. The degree to which specific organs are affected may depend on variation in genetic background among duplication carriers. Sensitivity to LIS1 dosage has been shown in the case of LIS1 reduction<sup>19</sup>, and we showed here sensitivity to increased LIS1 dosage. Compared to *PAFAH1B1* duplication, triplication of *PAFAH1B1* (subject 6) resulted in a more severe phenotype, including mental retardation and profound muscle hypotonia.

Collectively, our studies describe new genomic disorders in the MDS locus and further document that *de novo* duplication CNV can be complex and can occur by diverse mechanisms. We also provide evidence supporting genetic interactions between dosage-sensitive genes mapping within a CNV. Phenotypic analyses of LIS1-overexpressing mice at the cellular level revealed cell polarity and neuronal migration defects. Such subtle neuronal migration defects are not expected to be detected by MRI scans. Our findings suggest that brain and neurodevelopmental defects associated with other human neurocognitive impairments may not be detected by current brain imaging techniques. Our approach of identifying individuals with specific genomic changes through forward genomics and then establishing genotype-phenotype associations through reverse genomics, combined with analyses from a related mouse model, enables a partial explanation of the phenotypes observed in individuals with genomic rearrangements.

## Methods

### Subjects

Subjects and their family members were recruited from those with duplication in 17p13.3 as detected by clinical diagnostic testing using array CGH<sup>44-46</sup>. Clinical information and photographs were collected, and peripheral blood and/or DNA samples were obtained after informed consent using a protocol approved by the Institutional Review Board for Human Subject Research at Baylor College of Medicine.

### Identification of microduplication in 17p13.3 by array CGH

Microduplications in five subjects were identified in the Medical Genetics Laboratories at Baylor College of Medicine by clinical chromosomal microarray analysis using either a targeted BAC array (subjects 2, 5 and 7) or an oligonucleotide-based BAC emulsion array (subjects 1 and 6)<sup>44-46</sup>. Microduplications in subjects 3 and 4 were identified by Signature Genomics Laboratories and LabCorp, respectively. The array CGH experiments and data analysis have been described<sup>44-46</sup>. FISH analysis was done on phytohemagglutinin-stimulated peripheral blood lymphocytes according to a standard clinical protocol.

### Fine mapping by genome-wide oligonucleotide array

An Agilent custom 4 × 44K oligonucleotide array with 44,000 oligonucleotides spanning the entire short arm of human chromosome 17 at a resolution of 2 or 3 oligonucleotides per

kilobase of DNA sequence was used to fine-map the duplicated region. The normal reference controls for array CGH were purchased from the Coriell Institute for Medical Research (male, NA10851; female, NA15510). The array CGH experiments and data analysis have been described<sup>46</sup>.

### Generation of transgenic mice

Our transgenic construct was based on a vector designed for monitoring Cre recombinase activity<sup>47</sup>. A strong promoter, CAGG, comprising the cytomegalovirus enhancer and chicken  $\beta$ -actin promoter, drives the expression of a reporter gene (*lacZ*). The reporter is followed by a *neo*<sup>R</sup> cassette and is flanked by *loxP* sites. This construct allows the transgene to be expressed only after Cre excision of the *lacZ* reporter, the *neo*<sup>R</sup> cassette and three copies of the SV40 polyA signal that serves as a transcriptional stop. This system enables the selection of embryonic stem cell lines in which transgene integration allows widespread expression of the reporter. We constructed a LIS1-DsRed fusion protein that allowed us to monitor the expression of the transgene in the transfected clones and mice. The LIS1-DsRed protein has been extensively studied, and it faithfully represents the localization of the endogenous protein<sup>48</sup>. The resulting mice expressed the transgene *Tg(CAGG-loxP-LacZ-neo-loxP-PAFAH1B-DsRed)*. The *lacZ* reporter provides a quick and relatively easy genotyping method for the mice. The mouse lines were crossed with Swiss mice carrying the *Foxg1<sup>tm1(Cre)Skw</sup>* transgene<sup>49</sup> (*Foxg1(Cre)* mice), which expresses Cre in a restricted manner in the developing telencephalon starting at E9. The transgenic mice containing both the *LIS1-DsRed* and *Foxg1(Cre)* transgenes were designated *LIS1::Foxg1(Cre)*. For the above experiments, mice containing but not expressing the *LIS1-DsRed* transgene were used as a control, and in indicated experiments, wild-type mice were used as an additional control. Mice containing *Foxg1(Cre)* but not *LIS1-DsRed* were used for Cre expression control. For all of the parameters measured, there were no differences between the different controls. Mouse protocols were approved by the Institutional Animal Care and Use Committee of the Weizmann Institute.

### Measurement of Cdc42 activity

Cdc42 regulates molecular events by cycling between an inactive GDP-bound form and an active GTP-bound form. In its active state, Cdc42 binds specifically to the p21 binding domain of p21-activated protein kinase to control downstream signaling cascades. In the Cdc42 activation assay, this binding domain, bound to agarose beads, was used to selectively isolate and pull down the active form of Cdc42. Subsequently, the precipitated GTP-Cdc42 was detected by immunoblot analysis using an antibody to Cdc42 (ref. 50). The procedure was done using a Cdc42 activation assay kit (Upstate Biotechnology).

### Histology and immunostaining

Embryos were fixed with 4% paraformaldehyde in PBS. Embryos older than E14 were perfused and postfixed in paraformaldehyde overnight. Samples were cryoprotected in 20% sucrose-PBS overnight, embedded in OCT and cryosectioned (20  $\mu$ m). Paraffin wax-embedded samples were sectioned (5–6  $\mu$ m) and stained with the Nissl method using standard protocols. When required, BrdU was injected intraperitoneally (0.01 ml of 5 mg/ml

BrdU solution per gram body weight) into pregnant mice at the time points indicated. Immunostaining was done using 10% normal goat, fetal calf or horse serum, depending on the origin of the secondary antibody, in PBS with 0.1% Triton X-100 as a blocking reagent. The number of cells with phosphorylated histone H3 was determined by counting in a 300- $\mu$ m width area in the ventricular zone, up to four cell layers away from the ventricular surface. The following primary antibodies were used: rabbit antibody to calbindin (Swant Bellinzona), mouse antibody to pericentrin (BD Biosciences Clontech), rabbit antibody to pan-cadherin (Sigma), rabbit antibody to  $\beta$ -catenin (Sigma), rabbit antibody to Tbr2 (Chemicon), goat antibody to PAR-6DA (Santa Cruz Biotechnology), antibody to Numb (Developmental Studies Hybridoma Bank), mouse antibody to aPKC (BD Biosciences Clontech), rat antibody to BrdU (Serotec), rabbit antibody to phosphorylated histone H3 (Upstate Biotechnology) and Alexa Fluor 633-conjugated antibody to phalloidin (Molecular Probes). TUNEL staining was done using an Apop tag kit (Chemicon). DAPI (2.5  $\mu$ g/ml; Sigma) was included in the final wash buffer (PBS) for nuclear staining. Barrel labeling and oxcarbocyanine labeling are described in Supplementary Methods online.

### Electron microscopy

Brains of E12.5 embryos were fixed with 3% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4). Samples were embedded in 3.5% agarose and sectioned to 100- $\mu$ m-thick slices using a vibratome. Slices were washed in the same buffer and postfixed with 1% osmium tetroxide. After being stained with 2% uranyl acetate in water for 1 h at room temperature (24  $^{\circ}$ C), the slices were dehydrated in graded ethanol solutions and embedded in Epon 812. Ultrathin sections (70–90 nm thick) were prepared with a Leica UCTultramicrotome, analyzed under 120 kV on a Tecnai 12 transmission electron microscope (FEI) and digitized with Eagle (FEI) and MegaView III charge-coupled device cameras using AnalySIS and TIA software. The electron microscopy studies were conducted at the Irving and Cherna Moskowitz Center for Nano and Bio-Nano Imaging at the Weizmann Institute of Science.

### Live imaging

Brains were removed into cold L-15 supplemented with glucose (0.6%) and saturated with oxygen. Freshly isolated whole brains were sliced in a coronal orientation by vibratome (300  $\mu$ m) and then transferred onto inserts (MilliCell-CM; 0.4 mm; Millipore) floating on serum-free medium (Neurobasal medium supplemented with B27, N2, GlutaMax, glucose and gentamicin). Slices were incubated for 2 h before imaging. For nuclei visualization, Hoechst 333342 (Molecular Probes) was added to the medium prior to imaging. During time-lapse video microscopy, temperature was maintained at 37  $^{\circ}$ C. Analysis of movies was done using Imaris 6.1 (Bitplane).

### Statistical analysis

Statistical analysis was conducted using Prism 4 software (GraphPad Software).

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


We thank the participating families for their cooperation in the study, the members of the Chromosomal Microarray Analysis and Cytogenetic/FISH laboratories for technical assistance, G. Eichele for help with the *in situ* hybridization experiments, E. Arama and S. Haiderleu for useful comments and advice, S. McConnell for the *Foxg1(Cre)* mice and M. O'Gorman (Children's Memorial Hospital, Chicago) for assistance with specimen collection. The work was supported in part by the Israeli Science Foundation (grant no. 270/04 to O.R. and an equipment grant), the Foundation Jérôme Lejeune, the Minerva Foundation with funding from the Federal German Ministry for Education and Research, German-Israeli collaboration grant Gr-1905, March of Dimes grant 6-FY07-388, collaborative BSF grant 2007081 (to O.R. and J.R.L.), a grant from the Paul Godfrey Research Foundation in Children's Diseases, the Benozio Center for Neurological Diseases, the Kekst Center, the Forcheimer Center, a Weizmann-Pasteur collaborative grant, a research grant from the Michigan Women of Wisdom Fund to support Weizmann Women scientists, support from Maurice Janin, the Jewish Communal Fund, Albert Einstein College of Medicine of Yeshiva University, the David and Fela Shapell Family Center research grant for Genetic Disorders Research, grants DIGESIC-MEC BFU2005-09085 and Ingenio 2010 MEC-CONSOLIDER CSD2007-00023 (to S.M.), support from EU grant LSHG-CT-2004-512003, the Baylor Medical Genetics Laboratories, the Mental Retardation Developmental Disabilities Research Center (HD024064) and a Program Project grant (P01 HD39420) from the National Institute of Child Health and Human Development (to J.R.L.). O.R. is an Incumbent of the Bernstein-Mason professorial chair of Neurochemistry.

## References

1. Lupski JR. Genomic rearrangements and sporadic disease. *Nat Genet.* 2007; 39:S43–S47. [PubMed: 17597781]
2. Reiner O, et al. Isolation of a Miller-Dieker lissencephaly gene containing G protein beta-subunit-like repeats. *Nature.* 1993; 364:717–721. [PubMed: 8355785]
3. Barkovich AJ, Kuzniecky RI, Jackson GD, Guerrini R, Dobyns WB. A developmental and genetic classification for malformations of cortical development. *Neurology.* 2005; 65:1873–1887. [PubMed: 16192428]
4. Harding, B. Dysplasias of Cerebral Cortex and Epilepsy. Guerrini, R., editor. Lippincott-Raven; Philadelphia: 1996. p. 81-88.
5. Kamiya A, et al. A schizophrenia-associated mutation of *Drosoph.* *Inf. Serv.* C1 perturbs cerebral cortex development. *Nat Cell Biol.* 2005; 7:1167–1178. [PubMed: 16299498]
6. Schumacher J, et al. Strong genetic evidence of *DCDC2* as a susceptibility gene for dyslexia. *Am J Hum Genet.* 2006; 78:52–62. [PubMed: 16385449]
7. Walsh T, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science.* 2008; 320:539–543. [PubMed: 18369103]
8. Xu B, et al. Strong association of *de novo* copy number mutations with sporadic schizophrenia. *Nat Genet.* 2008; 40:880–885. [PubMed: 18511947]
9. Stefansson H, et al. Large recurrent microdeletions associated with schizophrenia. *Nature.* 2008; 455:232–236. [PubMed: 18668039]
10. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. *Nature.* 2008; 455:237–241. [PubMed: 18668038]
11. Sebat J, et al. Strong association of *de novo* copy number mutations with autism. *Science.* 2007; 316:445–449. [PubMed: 17363630]
12. Weiss LA, et al. Association between microdeletion and microduplication at 16p11.2 and autism. *N Engl J Med.* 2008; 358:667–675. [PubMed: 18184952]
13. Kumar RA, et al. Recurrent 16p11.2 microdeletions in autism. *Hum Mol Genet.* 2008; 17:628–638. [PubMed: 18156158]
14. Cardoso C, et al. Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other phenotypes secondary to deletions of 17p13.3. *Am J Hum Genet.* 2003; 72:918–930. [PubMed: 12621583]
15. Toyo-oka K, et al. 14–3-3 $\epsilon$  is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome. *Nat Genet.* 2003; 34:274–285. [PubMed: 12796778]
16. Mikhail FM, et al. Complete trisomy 17p syndrome in a girl with der(14)t(14;17)(p11.2;p11.2). *Am J Med Genet A.* 2006; 140:1647–1654. [PubMed: 16835929]

17. Morelli SH, Deubler DA, Brothman LJ, Carey JC, Brothman AR. Partial trisomy 17p detected by spectral karyotyping. *Clin Genet*. 1999; 55:372–375. [PubMed: 10422810]
18. Cahana A, et al. Targeted mutagenesis of *Lis1* disrupts cortical development and *LIS1* homodimerization. *Proc Natl Acad Sci USA*. 2001; 98:6429–6434. [PubMed: 11344260]
19. Hirotsune S, et al. Graded reduction of *Pafah1b1* (*Lis1*) activity results in neuronal migration defects and early embryonic lethality. *Nat Genet*. 1998; 19:333–339. [PubMed: 9697693]
20. Shu T, et al. *Ndel1* operates in a common pathway with *LIS1* and cytoplasmic dynein to regulate cortical neuronal positioning. *Neuron*. 2004; 44:263–277. [PubMed: 15473966]
21. Tsai JW, Bremner KH, Vallee RB. Dual subcellular roles for *LIS1* and dynein in radial neuronal migration in live brain tissue. *Nat Neurosci*. 2007; 10:970–979. [PubMed: 17618279]
22. Tsai JW, Chen Y, Kriegstein AR, Vallee RB. *LIS1* RNA interference blocks neural stem cell division, morphogenesis, and motility at multiple stages. *J Cell Biol*. 2005; 170:935–945. [PubMed: 16144905]
23. Peiffer DA, et al. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. *Genome Res*. 2006; 16:1136–1148. [PubMed: 16899659]
24. Lee JA, Carvalho CM, Lupski JRA. DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. *Cell*. 2007; 131:1235–1247. [PubMed: 18160035]
25. Dobyns WB, Reiner O, Carrozzo R, Ledbetter DH. Lissencephaly. A human brain malformation associated with deletion of the *LIS1* gene located at chromosome 17p13. *J Am Med Assoc*. 1993; 270:2838–2842.
26. Pilz DT, et al. *LIS1* and *XLIS* (*DCX*) mutations cause most classical lissencephaly, but different patterns of malformation. *Hum Mol Genet*. 1998; 7:2029–2037. [PubMed: 9817918]
27. Chenn A, Zhang YA, Chang BT, McConnell SK. Intrinsic polarity of mammalian neuroepithelial cells. *Mol Cell Neurosci*. 1998; 11:183–193. [PubMed: 9675050]
28. Tamamaki N, et al. Green fluorescent protein expression and colocalization with calretinin, parvalbumin, and somatostatin in the *GAD67-GFP* knock-in mouse. *J Comp Neurol*. 2003; 467:60–79. [PubMed: 14574680]
29. Lupski JR. Genomic disorders: structural features of the genome can lead to DNA rearrangements and human disease traits. *Trends Genet*. 1998; 14:417–422. [PubMed: 9820031]
30. Feller SM. Crk family adaptors-signalling complex formation and biological roles. *Oncogene*. 2001; 20:6348–6371. [PubMed: 11607838]
31. Assadi AH, et al. Interaction of reelin signaling and *Lis1* in brain development. *Nat Genet*. 2003; 35:270–276. [PubMed: 14578885]
32. Ballif BA, et al. Activation of a *Dab1/CrkL/C3G/Rap1* pathway in Reelin-stimulated neurons. *Curr Biol*. 2004; 14:606–610. [PubMed: 15062102]
33. Chen K, et al. Interaction between *Dab1* and *CrkII* is promoted by Reelin signaling. *J Cell Sci*. 2004; 117:4527–4536. [PubMed: 15316068]
34. Wall MA, Socolich M, Ranganathan R. The structural basis for red fluorescence in the tetrameric GFP homolog *DsRed*. *Nat Struct Biol*. 2000; 7:1133–1138. [PubMed: 11101896]
35. Ligon LA, Karki S, Tokito M, Holzbaur EL. Dynein binds to  $\beta$ -catenin and may tether microtubules at adherens junctions. *Nat Cell Biol*. 2001; 3:913–917. [PubMed: 11584273]
36. Yingling J, et al. Neuroepithelial stem cell proliferation requires *LIS1* for precise spindle orientation and symmetric division. *Cell*. 2008; 132:474–486. [PubMed: 18267077]
37. Hirokawa N, Takemura R. Molecular motors in neuronal development, intracellular transport and diseases. *Curr Opin Neurobiol*. 2004; 14:564–573. [PubMed: 15464889]
38. Reiner O, Sapoznik S, Sapir T. Lissencephaly 1 linking to multiple diseases: mental retardation, neurodegeneration, schizophrenia, male sterility, and more. *Neuromolecular Med*. 2006; 8:547–565. [PubMed: 17028375]
39. Cappello S, et al. The Rho-GTPase *cdc42* regulates neural progenitor fate at the apical surface. *Nat Neurosci*. 2006; 9:1099–1107. [PubMed: 16892058]
40. Chen L, et al. *Cdc42* deficiency causes Sonic hedgehog-independent holoprosencephaly. *Proc Natl Acad Sci USA*. 2006; 103:16520–16525. [PubMed: 17050694]

41. Kholmanskikh SS, Dobrin JS, Wynshaw-Boris A, Letourneau PC, Ross ME. Disregulated RhoGTPases and actin cytoskeleton contribute to the migration defect in Lis1-deficient neurons. *J Neurosci.* 2003; 23:8673–8681. [PubMed: 14507966]
42. Kholmanskikh SS, et al. Calcium-dependent interaction of Lis1 with IQGAP1 and Cdc42 promotes neuronal motility. *Nat Neurosci.* 2006; 9:50–57. [PubMed: 16369480]
43. Shen Y, et al. Nudel binds Cdc42GAP to modulate Cdc42 activity at the leading edge of migrating cells. *Dev Cell.* 2008; 14:342–353. [PubMed: 18331715]
44. Cheung SW, et al. Development and validation of a CGH microarray for clinical cytogenetic diagnosis. *Genet Med.* 2005; 7:422–432. [PubMed: 16024975]
45. Lu X, et al. Clinical implementation of chromosomal microarray analysis: summary of 2513 postnatal cases. *PLoS ONE.* 2007; 2:e327. [PubMed: 17389918]
46. Ou Z, et al. BAC-emulation oligonucleotide arrays for targeted clinical array CGH analyses. *Genet Med.* 2008; 10:278–289. [PubMed: 18414211]
47. Lobe CG, et al. Z/AP, a double reporter for cre-mediated recombination. *Dev Biol.* 1999; 208:281–292. [PubMed: 10191045]
48. Coquelle FM, et al. LIS1, CLIP-170's key to the dynein/dynactin pathway. *Mol Cell Biol.* 2002; 22:3089–3102. [PubMed: 11940666]
49. Hebert JM, McConnell SK. Targeting of cre to the *Foxg1* (BF-1) locus mediates loxP recombination in the telencephalon and other developing head structures. *Dev Biol.* 2000; 222:296–306. [PubMed: 10837119]
50. Benard V, Bohl BP, Bokoch GM. Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. *J Biol Chem.* 1999; 274:13198–13204. [PubMed: 10224076]

**Figure 1.**

Seven individuals with duplications of the MDS region identified by array CGH. (a) Duplicated regions in 17p13.3. Top, ideogram of human chromosome 17. Clones used in the array analyses are shown. Bottom, MDS region is indicated by yellow box. Below are seven horizontal bars showing fine-mapping of duplications. Red, duplication; green, deletion; blue, triplication. Subject 1 had the smallest duplication, containing only four genes (*TUSC5*, *YWHAE* (encoding 14-3-3 $\epsilon$ ), *CRK* and *MYO1C*), with the first exon of some *MYO1C* transcripts outside the duplicated region. An 82-kb deletion in the subteleromic




region distal to the MDS region was identified in subject 6. Green asterisk for subject 7 indicates ~4-kb deletion. TEL, telomere; CEN, centromere. (b–k) Gain of copy number (black arrows) in the MDS region was detected by array CGH (b–f) and confirmed by FISH (g–k). Clones with gain in copy number and probes for FISH are indicated. (h) Metaphase FISH analysis showing that the additional copy in 17p13.3 in subject 2 was inserted within the long arm of chromosome 13 (FISH signals indicated by red arrows). (j) Triplication in subject 6 was detected using a probe specific to *PAFAH1B1* (encoding LIS1). NI, normal; Dup, duplication; Trip, triplication.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 2.**

Facial features and mild brain structural anomalies identified by brain MRI. (a,b) Subject 1 had thick eyebrows, synophrys, full periorbital region, long straight eyelashes, large ears with thick fleshy earlobes, squared nose with overhanging columella and thin upper lip. (c,d) Subject 2 had broad forehead, upslanting palpebral fissures, wide nasal bridge, synophrys, squared nasal tip, thin upper lip and prominent chin. (e,f) Subject 3 had mild facial anatomic abnormalities, including prominent and wide nasal bridge, mildly deep-set eyes, prominent eyebrows and mild prognathia. (g) Subject 4 had a long face, mild synophrys, mild hypotelorism, upslanting palpebral fissures, prominent nasal bridge, overhanging columella, short philtrum and thin upper lip. (h) Subject 6 had microcephaly and high rounded palate. (i,j) Subject 5 had microcephaly, prominent forehead, triangular face, mild jaw retraction and thin upper lip. Subjects 1–4 had a duplication of *YWHAE*, and subjects 5 and 6 had a duplication or triplication of *PAFAH1B1*, respectively. (k) Sagittal view of unenhanced T1-weighted brain MRI of subject 6 showing reduced brain size,


mainly in the occipital cortex, and gross dysgenesis of the corpus callosum (arrow) especially affecting the splenium. (I) Sagittal view of T1-weighted brain MRI of subject 7 showing reduced brain size, mainly in the occipital cortex, thinning of the splenium of the corpus callosum (arrow) and very mild cerebellar volume loss. We obtained informed consent to publish these photographs.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript

**Figure 3.**

Rearrangement mechanisms revealed by high-density array CGH and junction sequences. (a–d) The region and size of chromosome aberrations were precisely mapped by array CGH using a high-density customized array specific for chromosome 17p. As indicated by the arrows below the plots, subject 1 (a) had a simple small duplication, whereas subject 5 (b) showed a complex duplication-normal-duplication pattern, and subject 6 (c) showed a complex duplication-triplication-duplication pattern. An additional small deletion of ~82 kb was identified ~2 Mb distal to the MDS region in subject 6. Subject 7 (d) had a large duplication containing a small deletion of ~4 kb. Shown below are PCR amplifications of the junction fragments using the primers indicated by the small arrows above. For subject 6,


the complex rearrangement in the MDS region was *de novo*, but the distal deletion was inherited from the father. For subject 7, the deletion within the duplicated region was inherited from the mother. (e) Sequence analysis of the duplication junctions. Top (purple), normal distal flanking sequence; bottom (blue), normal proximal flanking sequence; middle, duplication junction sequence. Identical nucleotides between proximal and distal flanking sequences are indicated by asterisks. Regions of complete homology between proximal and distal sequences are boxed. Microhomology is present at the junctions between flanking sequences in subjects 1 (6 bp) and 4 (2 bp). Case 3 showed homologous recombination between the two *AluSg* elements within a perfect 27-bp homology interval.



**Figure 4.**

LIS1-overexpressing mice have smaller brains with a disorganized ventricular zone. (a) Transgene expression was observed in the telencephalon of E12.5 LIS1-overexpressing mice (right) but not in Cre-control littermates (left). (b) LIS1-DsRed (85 kDa) is estimated to be 20% of endogenous LIS1 (46 kDa). (c,d) Cresyl violet staining of comparable E14.5 brain sections from control (c) and LIS1-overexpressing (d) mice. Scale bar size is given in micrometers. (e,f) Higher magnification of boxed areas in c (e) and d (f), showing noticeable reduction of brain width in LIS1-overexpressing brain (f). VZ, ventricular zone; SVZ, subventricular zone; IZ, intermediate zone; CP, cortical plate. (g,h) Hoechst 33342 staining of E13.5 live brain sections from control (g) and LIS1-overexpressing (h) mice. Cells in h were less organized. (i,j) E14.5 control (i) and LIS1 overexpressing (j) brain sections labeled with short (30 min) BrdU (red), combined with Tbr2 immunostaining (green) to label the ventricular and subventricular zones. (k,l) Immunostaining for phosphorylated histone H3 (red) in control (k) and LIS1-overexpressing (l) E14.5 brain sections. Nuclei were stained with DAPI (blue). Boxed areas highlight difference in number and organization of mitotic cells between k and l. (m,n) Immunostaining for nestin (red) in control (m) and


LIS1-overexpressing (**n**) E14.5 brain sections. Nuclei were labeled with DAPI. Nestin expression was higher in LIS1-overexpressing mice. (**o,p**) Detection of apoptotic (TUNEL-positive) cells (red) indicated by arrowheads in control (**o**) and LIS1-overexpressing (**p**) mice. Nuclei were labeled with DAPI. (**q**) Quantification of TUNEL-positive cells in E14.5 coronal slices (20  $\mu$ m thick) in Cre-control (*Foxg1(Cre)*) and LIS1-overexpressing (*LIS1::Foxg1(Cre)*) brains. \*\*\* $P < 0.001$ , \* $P < 0.05$ .



**Figure 5.**

LIS1-overexpressing mice show reduced cell polarity in the ventricular zone. **(a,b)** Immunostaining for  $\beta$ -catenin (red) in E14.5 brain sections from control **(a)** and LIS1-overexpressing **(b)** mice. Nuclei were labeled with DAPI (blue). Scale bar size is given in micrometers. **(c,d)** Staining for phalloidin-FITC (green) in E14.5 brain sections from control **(c)** and LIS1-overexpressing **(d)** mice. Fewer dense patches were observed in **d** compared to **c**. **(e,f)** Immunostaining for pericentrin (red) and phosphorylated histone H3 (green) in E14.5 brain sections of control **(e)** and LIS1-overexpressing **(f)** mice. Nuclei were labeled with DAPI. Wider distribution of centrosomes was observed in **f**. **(g,h)** Immunostaining for Numb (green) in E14.5 brain sections from control **(g)** and LIS1-overexpressing **(h)** mice. Wider cytoplasmic distribution of Numb was observed in **h**. **(i,j)** Immunostaining for pan-cadherin (green) in E14.5 brain sections from control **(i)** and LIS1-overexpressing **(j)** mice. Lower cadherin expression was observed in the apical surface of **j**. **(k-n)** Immunofluorescence for aPKC $\lambda$  (green), PAR6 (red) and nuclei (blue) in control **(k,m)** and LIS1-overexpressing **(l,n)** E14.5 brain sections. Arrowheads in **k** and **l** highlight discontinuity in aPKC immunostaining. PAR6 staining was markedly lower in **n** versus **m**. **(o-t)** Electron micrographs of E12.5 brain sections at two magnifications. **(o,r)** Control in which transgene was inserted without Cre. **(p,s)** Additional Cre control. **(q,t)** LIS1 overexpression. Disorganization and reduction in adherens junctions were observed at lower **(q)** and higher magnification **(t)** in LIS1-overexpressing brains. **(u)** Cdc42 activity, measured by pulling down GTP-bound form of Cdc42. Addition of GTP $\gamma$ S served as positive control; GDP served as negative control. Less Cdc42-GTP was detected in E15.5 LIS1-overexpressing brain lysates compared to control.





**Figure 6.**

Radial and tangential migration is delayed in LIS1-overexpressing mice. (**a,b**) Cresyl violet staining of E14.5 brain sections detected cortical plate (CP) in control (**a**) but not LIS1-overexpressing (**b**) mice. IZ, intermediate zone; VZ, ventricular zone. (**c**) BrdU labeling at E13.5 and analysis at E15.5 (mean  $\pm$  s.d.). A significant number of LIS1-overexpressing neurons in *LIS1::Foxg1(Cre)* mice did not reach more superficial areas of the cortex. Bins represent distance from the ventricle in micrometers. Bin 400–500,  $P = 0.012$ ; bin 300–400,  $P = 0.027$ ; bin 200–300,  $P = 0.043$  by Student t test.  $n = 5$ . (**d,e**) BrdU labeling at E13.5 and analysis at P0. Brain sections were immunostained for BrdU (red) and cell nuclei (DAPI; blue). BrdU-labeled LIS1-overexpressing cells (**e**) reached fewer superficial positions than did control cells (**d**), and LIS1-overexpressing brain width was thinner. (**f–h**) Tangential migration was reduced in LIS1-overexpressing mice. (**f–h**) GAD67-GFP-labeled interneurons (green) analyzed at E12.5. Shorter migratory route was undertaken in LIS1-overexpressing brain section (**h**) compared to two controls, transgene without Cre (**f**) and Cre without transgene (**g**). (**i–k**) GAD67-GFP-labeled interneurons (white) analyzed at E14.5. Shorter migratory route was undertaken in LIS1-overexpressing brain section (**k**) versus transgene without Cre (**i**) and Cre control (**j**). The arrowheads in **f–k** indicate the

dorsal edge of interneurons' tangential migratory stream in the pallium. **(l,m)** Reduced tangential migration detected by immunostaining for calbindin (red). Fewer cells were observed in boxed area for LIS1-overexpressing mice at P0 **(m)** compared to control mice **(l)**.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

<i>YWHAE</i> <i>TUSC5</i>	<i>MYO1C</i> <i>CRK</i>	<i>PFAFH1B1</i>	Clinical manifestations in humans	Phenotype in mice
		Del	Lissencephaly	+/- migration abnormalities; <i>Pafah1b1</i> <sup>cko/ko</sup> reduced brain size, migration abnormalities; -/- early embryonic lethal
Del			DD	+/- mild migration abnormalities; -/- severe migration abnormalities
Del			MDS	More severe migration abnormalities
		Dup	DD, relative microcephaly, mild brain structural anomalies, exacerbated further with triplication vs. duplication	Reduced brain size, abnormal ventricular zone, migration abnormalities
Dup			DD, facial dysmorphology	N/A
	Dup		DD, facial dysmorphology, overgrowth	N/A
		Dup	DD, mild brain structural anomalies	N/A

**Figure 7.**

Clinical manifestations observed in affected individuals with deletions or duplications of dosage-sensitive genes within the MDS region and comparable phenotypes in transgenic mice. We considered copy numbers of the two MDS crucial genes, *PFAFH1B1* and *YWHAE*, as well as *CRK* and *MYO1C*. *TUSC5* is also shown because its role in MDS and 17p13.3 duplication is still unknown. Phenotypes in *Pafah1b1*-mutant mice are dosage sensitive<sup>19</sup>: heterozygous mice (~45%) showed disorganization in the cortex, hippocampus and olfactory bulb; *Pafah1b1*<sup>cko/ko</sup> mice with further reduction (~35%) showed defects analogous to human lissencephaly, such as disorganized cortical layers, microcephaly and cerebellar defects. Mild structural anomalies in individuals with *PFAFH1B1* duplication include dysgenesis of the corpus callosum and mild volume loss in the cerebellum, occipital cortex and cerebrum. Del, deletion; Dup, duplication; DD, developmental delay; -/-, homozygous mutants; +/-, heterozygous mutants; N/A, not available.

**Table 1**  
**Clinical features of individuals with duplications or triplication in the 17p13.3 MDS region**

	Subject 1	Subject 2	Subject 3	Subject 4	Subject 5	Subject 6	Subject 7
Sex	Male	Female	Male	Male	Male	Male	Female
Duplication size (Mb)	0.24	0.35	0.61	1.41	0.78	Tri./dup. 0.63	3.6
Parental studies	<i>De novo</i>	Mother normal	<i>De novo</i>	<i>De novo</i>	Mother dup.	<i>De novo</i>	<i>De novo</i>
Age at exam	5 y, 5 mo	9 y, 9 mo	33 mo	14 y, 9 mo	32 mo	17 y, 4 mo	10 y, 5 mo
Birth weight (percentile)	75th	+3 s.d.	10th	95th	10th	N/A	25th
Birth length (percentile)	N/A	+3 s.d.	N/A	+3 s.d.	N/A	N/A	75th
Birth FOC (percentile)	N/A	N/A	N/A	N/A	N/A	N/A	10th
Current weight (percentile)	90th	+3 s.d.	50th	95th	-3 s.d.	-5 s.d.	95th
Current length (percentile)	90th	+3 s.d.	50th	97th	-3.5 s.d.	-6 s.d.	75th
Current FOC (percentile)	75th	+2.5 s.d.	10th	90th	-4 s.d.	N/A	10th
Head and neck	Normal	Long face	Normal	Long face	Microcephaly, triangular face	Microcephaly	Normal
Eyes	Thick eyebrows, synophrys, full periorbital region, long straight eyelashes	Synophrys, upslanting palpebral fissures	Deep-set eyes, prominent eyebrows	Mild synophrys, upslanting palpebral fissures, hypotelorism	Normal	Normal	Infantile strabismus
Nose	Squared nose, overhanging columella	Prominent nasal bridge, overhanging columella, squared nose	Broad nasal bridge	Prominent nasal bridge, overhanging columella, recurrent nosebleeds	Normal	Normal	Normal
Mouth	Thin upper lip, wide groove, narrow high palate	Thin upper lip, prominent chin	Mild prognathia	Thin upper lip, short philtrum, malocclusion	Micrognathia	High arched palate	Normal
Ears	Large ears; thick, fleshy earlobes	Large ears	Normal	Normal	Normal	Normal	Normal
Skeletal	Small distal phalanges, large hands (97th percentile)	Large hands with mid-palm length >97th percentile	Normal	Scoliosis, advanced bone age, prominent PIP joints	Sagittal cranio-synostosis	Scoliosis, dislocated hips, varus leg deformity, short stature	Normal
Development	Mild developmental delay	Global developmental delay	Expressive language delay	Fine motor delay	Failure to thrive, developmental delay	Mental retardation	Moderate developmental delay
Neurological abnormalities	Mild muscle hypotonia, suspected autism	Muscle hypotonia	Reduced eye contact	Attention deficit disorder with hyperactivity	Not available	Profound muscle hypotonia, muscle atrophy, ADHD, OCD	Insensitivity to pain, autism

Tri., triplication; dup., duplication; y, year; mo, month; N/A, not available; FOC, fronto-occipital circumference; PIP, proximal interphalangeal; ADHD, attention deficit-hyperactivity disorder; OCD, obsessive-compulsive disorder.